STAFF REPORT ISB: Dr. Muhammad Yar, an Assistant Professor at Interdisciplinary Research Centre in Biomedical Materials, COMSATS Institute of Information, Lahore, has developed a new drug that may be useful for the treatment of several CNS disorders such as Parkinson disease, anxiety, depression, epilepsy, Alzheimer disease, sleep disorders, attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD).
The invention has been successfully registered with US Patent having Number US 9169221 B2 on October, 2015. The Patent title is DIHYDRO 1,4-BENZOXAZINES AND METHOD OF SYNTHESIZING THE SAME USING SULFONIUM SALTS.
Benzoxazines have been known to exhibit interesting pharmacological properties. They are integral part of URAT inhibitors, a potent therapy for gout disease.
Benzoxazine derivative, (6-tert-butyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-3-yl)-methanol (TBM) may be cell growth inhibitor which inhibit the proliferation of p53 wild-type lung adenocarcinoma cells.
The 5-Hydroxytryptamine (5-HT6) receptor messenger RNA (mRNA) occupy high level of receptors in the brain, which mediates the actions of the neurotransmitter 5-hydroxytryptamine (5-HT). Benzoxazine derivatives may be used for modulating (5-HT) receptors, especially 5-HT.
This is the first US patent that is registered from CIIT, Lahore, and is a reflection of the most outstanding standard of work being carried out in any Pakistani University.
Dr. Yar has expressed that that day is not very far when Pakistani patients would find locally developed solutions for their treatments in low prices.